Objective:

To explore the current state and future directions of radiosensitization strategies in the treatment of locally advanced cervical cancer (LACC).

Approach:

Key Findings:

• Cisplatin has been the standard radiosensitizer for LACC since the 1990s, despite advancements in radiation techniques.
• ADCs and ICIs have improved survival rates in metastatic cervical cancer but require further study in LACC.
• Current clinical trials of DNA damage response inhibitors have not shown effective tumor control and may increase normal tissue damage.

Interpretation:

Multimodal ADC-radio-immunotherapy may offer a beneficial approach for LACC, warranting further investigation.

Limitations:

• Lack of clinical trials studying ADCs and ICIs specifically in the LACC population.
• Previous trials of DNA damage response inhibitors have not yielded positive outcomes.

Conclusion:

The integration of novel therapies with existing treatment modalities may enhance outcomes for patients with locally advanced cervical cancer.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.